CL2011001943A1 - Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso. - Google Patents

Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.

Info

Publication number
CL2011001943A1
CL2011001943A1 CL2011001943A CL2011001943A CL2011001943A1 CL 2011001943 A1 CL2011001943 A1 CL 2011001943A1 CL 2011001943 A CL2011001943 A CL 2011001943A CL 2011001943 A CL2011001943 A CL 2011001943A CL 2011001943 A1 CL2011001943 A1 CL 2011001943A1
Authority
CL
Chile
Prior art keywords
bowel syndrome
irritable bowel
treat
antibiotic therapy
prevent post
Prior art date
Application number
CL2011001943A
Other languages
English (en)
Inventor
Mark Chang Christopher Pimentel
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CL2011001943A1 publication Critical patent/CL2011001943A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para reducir la probabilidad de padecer el síndrome del intestino irritable post-infeccioso (PI-IBS) mediante la administración de un antibiótico.
CL2011001943A 2009-02-11 2011-08-10 Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso. CL2011001943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15177209P 2009-02-11 2009-02-11

Publications (1)

Publication Number Publication Date
CL2011001943A1 true CL2011001943A1 (es) 2012-02-03

Family

ID=42562059

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001943A CL2011001943A1 (es) 2009-02-11 2011-08-10 Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.

Country Status (8)

Country Link
US (1) US20110294726A1 (es)
EP (1) EP2396029A4 (es)
AU (1) AU2010213773B2 (es)
BR (1) BRPI1008058A8 (es)
CA (1) CA2752020A1 (es)
CL (1) CL2011001943A1 (es)
MX (1) MX2011008354A (es)
WO (1) WO2010093776A1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10466254B2 (en) 2012-09-17 2019-11-05 Cedars-Sinai Medical Center Method of measuring a level of anti-vinculin antibodies in a biological sample
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
PT2493471T (pt) * 2009-10-26 2020-01-09 Borody Thomas J Nova terapia de combinação entérica
CN103562240B (zh) * 2011-06-03 2017-02-15 巴斯夫欧洲公司 连续制备吸水性聚合物颗粒的方法
WO2013112809A2 (en) * 2012-01-25 2013-08-01 Salix Pharmaceuticals, Ltd Rifaximin derivative and uses thereof
ES2691485T3 (es) * 2012-10-10 2018-11-27 Stc.Unm Métodos para el diagnóstico de infecciones bacterianas
WO2016057772A1 (en) 2014-10-09 2016-04-14 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
CA3018872A1 (en) * 2016-03-24 2017-09-28 Paratek Pharmaceuticals, Inc. Methods of treating a bacterial infection in a subject at risk of developing c. difficile infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133348T3 (de) * 1990-10-22 2011-05-12 Centre for Digestive Diseases Pty, Ltd. Behandlung von nicht-entzündlichen darmerkrankungen
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
US20040106590A1 (en) * 2002-08-29 2004-06-03 Barry Eisenstein Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
DK1698698T3 (da) * 2003-12-05 2014-05-12 Fuso Pharmaceutical Ind Cytolethaldistenderende toksingener som mål for detektering af campylobacterbakterier
US20090233888A1 (en) * 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
EP2054066B1 (en) * 2006-08-02 2015-04-15 Salix Pharmaceuticals, Inc. Methods for treatment of radiation enteritis
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
PT2252148T (pt) * 2008-02-26 2020-01-23 Salix Pharmaceuticals Ltd Métodos de tratamento da síndrome do intestino irritável

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US10466254B2 (en) 2012-09-17 2019-11-05 Cedars-Sinai Medical Center Method of measuring a level of anti-vinculin antibodies in a biological sample
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
EP2396029A1 (en) 2011-12-21
BRPI1008058A8 (pt) 2018-03-27
AU2010213773B2 (en) 2014-07-17
EP2396029A4 (en) 2012-08-08
BRPI1008058A2 (pt) 2016-03-15
MX2011008354A (es) 2011-09-06
CA2752020A1 (en) 2010-08-19
US20110294726A1 (en) 2011-12-01
WO2010093776A1 (en) 2010-08-19
AU2010213773A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX391175B (es) Macrociclos peptidomimeticos.
CR20120448A (es) Compuesto heterocíclico
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201290919A1 (ru) Индазольные соединения и их применение
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
DOP2012000006A (es) Agonista de gpr119
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201101477A1 (ru) Органические соединения и их применение
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
MY151104A (en) Novel use
EA201170121A1 (ru) Лечение инфекций, вызванных антибиотикоустойчивыми бактериями
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CO6670518A2 (es) Tratamiento de infecciones de clostridium difícile en pacientes bajo terapia con antibióticos
IN2014DN03010A (es)
BR112013009185A2 (pt) uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável.
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes